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Abstract In sporadic Alzheimer’s disease (AD), neuro-
ﬁbrillary lesion formation is preceded by extensive post-
translational modiﬁcation of the microtubule associated
protein tau. To identify the modiﬁcation signature associ-
ated with tau lesion formation at single amino acid
resolution, immunopuriﬁed paired helical ﬁlaments were
isolated from AD brain and subjected to nanoﬂow liquid
chromatography–tandem mass spectrometry analysis. The
resulting spectra identiﬁed monomethylation of lysine
residues as a new tau modiﬁcation. The methyl-lysine was
distributed among seven residues located in the projection
and microtubule binding repeat regions of tau protein, with
one site, K254, being a substrate for a competing lysine
modiﬁcation, ubiquitylation. To characterize methyl lysine
content in intact tissue, hippocampal sections prepared
from post mortem late-stage AD cases were subjected to
double-label confocal ﬂuorescence microscopy using anti-
tau and anti-methyl lysine antibodies. Anti-methyl lysine
immunoreactivity colocalized with 78 ± 13% of neuroﬁ-
brillary tangles in these specimens. Together these data
provide the ﬁrst evidence that tau in neuroﬁbrillary lesions
is post-translationally modiﬁed by lysine methylation.
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Introduction
Alzheimer’s disease (AD) is deﬁned in part by the
appearance of intracellular inclusions composed of the
microtubule associated protein tau [35]. The mechanisms
that drive tau lesion formation in the highly prevalent
sporadic form of AD are not fully understood, but appear to
involve abnormal post-translational modiﬁcations (PTMs)
that inﬂuence tau function, stability, and aggregation pro-
pensity [45]. For example, hyperphosphorylation of tau
protein on certain hydroxy amino acids favors lesion for-
mation by dissociating tau from its microtubule binding
partner [4, 7] and by directly raising its rate and extent of
aggregation [1, 9, 48]. Although tau phosphorylation state
is mediated directly by phosphotransferases, it also is
modulated by competing modiﬁcations on hydroxy amino
acids such as O-linked b-N-acetylglucosaminylation (O-
GlcNAcylation) [40]. The reciprocal relationship between
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inhibitors, which by increasing O-GlcNAcylation, lower
phosphorylation stoichiometry and depress neuroﬁbrillary
lesion formation [65]. In addition to hydroxy amino acids,
Lys residues are modiﬁed on tau protein, and these too can
inﬂuence tau metabolism and aggregation. For example,
ubiquitylation of tau at Lys residues modulates intracellular
tau levels [53, 61], the magnitude of which affects both
nucleation and extension phases of the aggregation reaction
[12]. Together these observations suggest that tau aggre-
gation is under complex regulatory control that involves
crosstalk among diverse and sometimes competing PTMs.
To gain insight into the tau PTM signature most closely
associated with neuroﬁbrillary lesion formation at single
amino acid resolution, we have begun mapping modiﬁca-
tions on authentic, paired helical ﬁlaments (PHFs) isolated
from AD brain using mass spectrometry methods, with
special emphasis on Lys modiﬁcations [13]. Preliminary
analysis identiﬁed K254, K311, and K353 within the tau
microtubule binding repeat region as ubiquitylation sites
that were at least partially occupied in PHFs [13]. Recently,
acetylation was discovered as another Lys-directed tau
modiﬁcation associated with tau-bearing lesions in AD and
frontotemporal dementia [11, 46]. Tau acetylated in vitro
resulted in occupation of diverse sites that overlapped with
those we had determined to be ubiquitylated in disease
[46]. Therefore, acetylation is another candidate modiﬁ-
cation for regulating tau turnover indirectly through the
ubiquitin–proteasome system [46]. Moreover, in other
biochemical pathways, such as histone-mediated control of
gene expression, certain acetylated Lys residues can
alternatively be methylated, contributing to complex cross-
talk among Lys and hydroxyl amino acid modiﬁcations
[36]. These observations suggest that the web of tau PTMs
is potentially complex, with Lys-directed modiﬁcations
playing key regulatory roles with respect to rates of tau
turnover and aggregation.
Here we extend our characterization of PHF-tau using
mass spectrometry methods by expanding search criteria to
include both acetyl- and methyl-lysine modiﬁcations.
Although we found no evidence for tau acetylation/tri-
methylationatthelevelofdetectionavailableinourdatasets,
the results show that Lys monomethylation is a widespread
PHF-taumodiﬁcation.Thesedatarevealtaumethylationasa
new tau PTM accompanying PHF deposition in vivo.
Materials and methods
Subjects and tissue preparation
This study used only archival, de-identiﬁed post mortem
brain tissue samples from autopsies performed with
informed consent of each patient or relative via procedures
approved by the relevant institutional committees (Uni-
versity of Rochester, USA). Paraformaldehyde-ﬁxed brain
tissue was obtained from six elderly subjects with a clinical
diagnosis of AD [mean age 80 ± 10 years (SD)] that was
conﬁrmed on neuropathological evaluation in which the
Consortium to Establish a Registry for AD (CERAD) age-
adjusted criteria were met [47], and from four pathologi-
cally normal controls [mean age 62 ± 10 years (SD)]
without history of neurologic or psychiatric disorders. All
AD cases satisﬁed criteria for Braak stages V or VI,
whereas none of the control cases met pathological criteria
for AD [6].
Afﬁnity puriﬁcation of PHF-tau and enzymatic
digestion
PHF-tau was isolated from pooled, late-stage (Braak stages
V or VI) AD neocortical regions by immunoafﬁnity chro-
matography (MC1 monoclonal antibody) as described
previously [30]. PHF-tau was digested in solution in the
presence of 40% methanol with either trypsin (Promega) or
Lys-C (Sigma) followed by phosphopeptide enrichment
(Immobilized gallium, Thermo Fisher Scientiﬁc) as
detailed earlier [13].
Reductive methylation of recombinant human 4R tau
Reductive methylation was done as described previously
with minor modiﬁcations [18]. Brieﬂy, lyophilized
recombinant full-length human 2N4R tau (100 lg) was re-
suspended in 100 ll of 0.1 M citrate buffer (pH 6) and
methylated (room temperature for 2 h) in the presence of
0.1 M sodium cyanoborohydride and 20 mM formalde-
hyde. Reaction products were separated from reactants by
spin dialysis in 100 mM ammonium bicarbonate, pH 7.8.
Liquid chromatography–tandem mass spectrometry
(LC–MS/MS)
Mass spectrometric analysis of PHF-tau was performed
using an LTQ ion trap mass spectrometer controlled by
Xcalibur v.1.4 software (Thermo Electron) coupled online
to a nanoﬂow XTreme Simple LC system (CVC Micro-
Tech) as previously described [13]. Brieﬂy, peptides were
either loaded onto a trap column (Agilent Zorbax C18
guard column, or Michrom Bioresources peptide cap trap)
or loaded directly into the sample loop with 95% solvent A
(2% acetonitrile, 0.1% formic acid) and 5% solvent B (95%
acetonitrile, 0.1% formic acid). A 60 min linear gradient of
5–25% solvent B was used to elute the peptides from the
reverse phase column (150 mm 9 75 lm, 5 lm 300 A ˚
C18; CVC Micro-Tech).
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ionization source (Thermo Electron) using an uncoated
10 lm i.d. SilicaTip PicoTip nanospray emitter (New
Objective). The spray voltage of the mass spectrometer was
2.0 kV and the heated capillary temperature was 200C.
The top ﬁve ions in each MS1 scan were selected for MS/
MS fragmentation. After ions were selected for MS/MS
fragmentation twice within 30 s, they were dynamically
excluded for 30 s. An MS3 scan was triggered if, among
the three most abundant ions in the MS/MS scan, a neutral
loss of 98, 49, or 32.7 Da (corresponding to a loss of
H3PO4 from 1?,2 ?,o r3 ? precursor ions, respectively)
was detected. Other mass spectrometric data generation
parameters were as follows: collision energy 24% (35% for
MS3 scans), MS scan range 400–1,800 m/z, minimum MS
signal intensity 500 counts, minimum MS/MS signal
intensity 100 counts, and MS/MS activation time 120 ms
(30 ms for MS3 scans).
Analysis of mass spectrometric data
Spectra were searched against a UniProtKB human pro-
tein database (version Oct 5, 2010; 20,259 reviewed
sequences; 75,498 non-reviewed sequences) using Bio-
works 3.3.1 SP1 with the SEQUEST algorithm. Search
parameters included 1.5 amu peptide mass tolerance, 1.0
amu fragment tolerance, static Cys ?57 (carbamidome-
thylation) modiﬁcation and the following differential
modiﬁcations: Met ?16 (oxidation); Ser, Thr, Tyr ?80
(phosphorylation); Ser, Thr -18 (dehydroalanine and
2-amino-dehydrobutyric acid, respectively); Lys, Asp, Glu
?14 (monomethylation); Lys ?28 (dimethylation); Lys
?42 (trimethylation/acetylation); and Lys ?114 (ubiqui-
tylation). Fully enzymatic (trypsin or Lys-C) peptides
with up to two missed cleavages and charge-state
dependent cross correlation (XCorr) scores C1.5, 2.5, and
3.0 for 1?,2 ?, and 3? peptides, respectively, and DCn
[0.1 were considered as initial positive identiﬁcations.
All MS/MS and MS3 spectra of identiﬁed post-transla-
tionally modiﬁed peptides from the initial screening were
subjected to manual veriﬁcation.
All raw data from this study are freely available to the
research community on our laboratory’s website, http://
www.proteomeumb.org, which also serves as a data-shar-
ing portal. The original raw data are also available from
http://proteomecommons.org with the following Hash IDs:
Tau trypsin digestion dataset: (Y297YWVSnnKcaY3jSn
QkuCWj7tA1mls59uBBjjBpyqF5hOQ4lSmAuWNhvtdC1
EQCsj5A7 XFM0/3zj9YvVUIJlIuuwcoAAAAAAAABrA==);
Tau Lys-C digestion dataset: (pNmgHCue Fwyw3vtAgIdK
GatW5G8weUl7ArA/Fg?OlChNsahHADGSEQp7iUAOz
ouc81DMfWpeq7Ii1pDcjOkrs1h9BHAAAAAAAAAB
pg==).
Antibodies
Anti-tau mouse monoclonal antibodies Tau5 [43] and AT8
[22] were obtained from Dr. L. I. Binder (Northwestern
University Medical School) and Endogen (Woburn, MA),
respectively. Rabbit polyclonal anti-methyl lysine (meK)
antibody was obtained from Enzo Life Sciences (ADI-
KAP-TF121; Plymouth Meeting, USA). Cy3-conjugated
goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat
anti-mouse secondary antibodies were from Jackson
Immuno Research Laboratories, Inc (West Grove, USA)
and Invitrogen (Carlsbad, USA), respectively. Horseradish
peroxidase-conjugated goat anti-rabbit IgG secondary
antibody used for Western Blot was from Kirkegaard and
Perry Laboratories Inc (Gaithersburg, USA).
Immunohistochemistry
Coronal hippocampal tissue sections were cut (20 lm
thickness) and processed for immunohistochemistry as
described previously [17, 33]. Sections were rehydrated in
PBST (2.7 mM KCl, 0.14 M NaCl, 8.1 mM Na2HPO4,
0.1% Tween-20, pH 7.4) and ﬁxed (10 min) in ice cold
methanol. After 3 9 5 min rinses in PBST, sections were
blocked (1 h at 19C) with 5% goat serum diluted in PBST,
then incubated (overnight at 4C) with primary antibodies
diluted in 2.5% goat serum (Tau5, 1 lg/ml; Anti-meK,
0.3 lg/ml; AT8, 0.1 lg/ml). After washing in PBST
(3 9 10 min), sections were incubated (1 h at 19C) with
ﬂuorescent dye-labeled secondary antibodies (1.5 lg/ml
Cy3-conjugated goat anti-rabbit IgG; 2 lg/ml Alexa Fluor
488-conjugated goat anti-mouse IgG). After washing in
PBST (3 9 5 min), tissue was treated (10 min at 19C)
with 0.1% Sudan Black B (EM Diagnostics, Gibbstown,
USA) in 80% ethanol to suppress lipofuscin autoﬂuores-
cence [59]. Sections were then washed (2 9 5 min) in
PBST and once for 5 min in 33 mM NaH2PO4,162 mM
Na2HPO4, pH 7.4. Coverslips were mounted with Vecta-
shield (Vector Laboratories, Burlingame, USA) and sealed
with clear nail enamel. Labeled sections were viewed in a
Leica TCS SL laser-scanning confocal system (409 oil
HCX Plan Apo CS 0.75–1.25 NA or 1009 oil HCX Plan
Apo CS 0.70–1.40 NA objective lens) operated at wave-
lengths optimized for simultaneous detection of Alexa
Fluor 488 (kex = 488 nm; kem = 500–530 nm), and Cy3
(kex = 543 nm; kem = 560–600 nm). Long wavelength
ﬂuorescence (kex = 633 nm; kem = 650–740 nm) also
was monitored to assess autoﬂuorescence intensity. Digital
confocal images were captured at 19 and 39 digital zoom,
and stored in Tagged Image Format. Both secondary
antibodies displayed minimal non-speciﬁc staining under
these conditions as determined by immunostaining in the
absence of primary antibodies. For immunoadsorption
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(0.1 lg/ml) were diluted in 2.5% goat serum containing
2000-fold molar excess of recombinant 2N4R tau
(0.52 mg/ml) and incubated overnight (4C) with agitation.
Pellets were separated by centrifugation at 30,0009g for
30 min, and the supernatant was used for immunohisto-
chemistry as described above.
Analytical methods
The proportion of meK-positive lesions was estimated
using the Wilson score method [17, 49]. Sufﬁcient tech-
nical replicates (deﬁned as Tau-positive bodies at least
7 lm in both length and width) were counted from at least
ﬁve ﬁelds of each case so that the Wilson 95% conﬁdence
interval for colocalization was\15%. Overall mean colo-
calization was then calculated as the average of all six
biological replicate means and reported ± standard
deviation.
Results
PHF-tau is methylated in its N-terminal projection
and microtubule binding domains
To identify sites of Lys modiﬁcation in PHF-tau, previ-
ously collected MS datasets obtained from two
independent preparations of authentic AD-brain derived
PHFs (digested with either trypsin or Lys-C proteases;
[13]) were interrogated using the SEQUEST database
search algorithm programmed to identify unmodiﬁed Lys
residues along with sites of monomethylation (K ? 14),
dimethylation (K ? 28), trimethylation (K ? 42),
acetylation (also K ? 42), and ubiquitylation (K ? 114).
Sequence coverage in these datasets included 25 out of the
44 Lys residues present in the longest form of human brain
tau protein (2N4R tau, Fig. 1). This sequence coverage is
based on only the unmodiﬁed, lysine-modiﬁed (methylated
and ubiquitylated) and phosphorylated forms of PHF-tau.
Although these search conditions conﬁrmed three sites of
ubiquitylation in the microtubule binding repeat region
(K254, K311, and K353; [13]), no evidence for either
K ? 28 or K ? 42 masses was found, indicating that
dimethyl-, trimethyl-, and acetyl-lysine were not present in
the coverage area at the level of detection available in our
datasets. However, robust monomethylation was identiﬁed
at seven sites distributed throughout the tau sequence
(Table 1). Three of the sites (K163, K174, and K180)
reside within the proline-rich region of the tau N-terminal
projection domain, which mediates interactions with
microtubule-associated proteins such as actin [27] and the
Src homology three domain of plasma membrane-associ-
ated proteins including Src family kinases [37] and
phospholipase Cc [54]. In contrast, K254, K267, and K290
are part of the ﬁrst and second repeats of the microtubule-
binding domain. They reside within or adjacent to the core
b-sheet region of ﬁlamentous tau in vivo [50] and ﬂank the
‘‘PHF6*’’ sequence that modulates ﬁbrillation rate of
recombinant monomeric 4R tau in vitro [29, 39, 64].
Together these data reveal that PHF-tau is monomethylated
in vivo, and that the major occupied sites distribute across
protein segments known to mediate tau-protein interactions
(including tubulin binding and self association).
To assess the relative abundances of methylated, ubiq-
uitylated, and unmodiﬁed PHF-tau peptides, data were
subjected to spectral counting, which measures the number
of times a peptide is identiﬁed by MS/MS. Because spectral
Fig. 1 Summary of modiﬁcation sites identiﬁed by LC–MS/MS on
immunopuriﬁed PHF-tau. The sequence shown is that of human
2N4R tau (NCBI accession number NP_005901). Bold sequence
coverage; Red PHF6 and PHF6* motifs; dashed lines segments
encoded by alternatively spliced exons 2, 3, and 10; underline repeat
region (as deﬁned in [23]); P Phosphorylated sites, U Ubiquitylated
sites, me1 monomethylated sites identiﬁed from MS analysis reported
herein and in [13]
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have been employed for relative quantiﬁcation in many
label-free proteomic studies [10, 51, 56, 57, 66]. Relative
abundance was calculated by dividing the spectral count of
a modiﬁed peptide by the sum of the spectral counts of all
its forms (i.e., modiﬁed and unmodiﬁed). Results showed
that the relative abundance of monomethylation varied
among sites, from12% (K290) to as high as 67% (K180 and
K267) (Fig. 2). The relative abundance of ubiquitylation
also varied, from 1% (K254) to 33% (K311) (Fig. 2).
These data indicate that Lys modiﬁcation occupancies are
substantial in PHF tau.
Lys methylation participates in competitive crosstalk
with ubiquitylation
The sites of monomethylation identiﬁed above directly
overlapped with sites previously identiﬁed as being acet-
ylated in vitro (K174, K180; [46]) or ubiquitylated in vivo
(K254; [13]), raising the issue of competitive crosstalk at
these residues. Although no Lys acetylation was detected at
these sites in our datasets, it was possible to quantify rel-
ative methylation and ubiquitylation of K254. Methylated
K254 was identiﬁed in Lys-C peptide aa241-254 from
manually veriﬁed MS/MS spectra (Fig. 3). Relative to the
1 ? charge state y-ions of unmodiﬁed aa241–254 peptide
(Fig. 3a), the y-ions of methylated aa241–254 were shifted
by ?14 Da (Fig. 3b), reﬂecting the mass of the methyl
group (CH3) added to (and the H atom lost from) the e-
amino group on the K254 side chain. The appearance of the
?14 Da shift was not likely an artifact of Fischer esteriﬁ-
cation (i.e., chemical methylation of free carboxylic acid
groups in Asp and Glu; [32, 44]), because all MS/MS
spectra were unambiguously assigned by SEQUEST
(examples are shown in Supplemental Table 1). Moreover,
care was taken to limit Fischer esteriﬁcation conditions
during sample preparation by maintaining the pH of
digestion buffers [8, by avoiding exposure of samples to
high concentrations of methanol in the presence of acetic
acid, and by avoiding methanol as a co-solvent during LC
separation of the peptides.
Ubiquitylated-K254 was identiﬁed in tryptic peptide
aa243–257, which was resistant to protease cleavage at
K254 owing to the isopeptide bond formed between
ubiquitin and K254 (Fig. 3c). When aa241–254 and aa243–
257 peptides were subjected to spectral counting, 41% of
aa241–254 was monomethylated, whereas only1% of
aa243–257 was ubiquitylated (Table 2; Fig. 2). These data
Table 1 Lys methylation sites identiﬁed on PHF-tau
aa Residues Peptide Methyl site Charge state(s) PHF-tau domain XCorr score D Cn
25–44 DQGGYTMHQDQEGDTDAGLK K44 3? N 4.07 0.16
151–163 IATPRGAAPPGQK K163 2? N, P 3.28 0.42
164–174 GQANATRIPAK K174 2? N, P 3.03 0.28
175–180 TPPAPK K180 1? N, P 1.59 0.33
241–254 SRLQTAPVPMPDLK K254 2?/3? M, R1 3.71/3.55 0.41/0.24
258–267 SKIGSTENLK K267 2? M, R1 3.14 0.40
281–290 KLDLSNVQSK K290 2? M, R2 3.56 0.28
Lys-C and trypsin in-solution digests of PHF-tau were analyzed by nanoﬂow LC–MS/MS and the data were searched against a human database
using Bioworks with the SEQUEST algorithm
Amino acids in bold indicate identiﬁed methylated Lys residues. Amino acid (aa) residue numbering is based on the human 2N4R tau isoform
(NCBI accession number NP_005901). Cross-correlation (XCorr) and Delta correlation (DCn) scores are two metrics in the SEQUEST algorithm
used to assess the quality of candidate peptides assigned to MS/MS spectra. Peptides with charge-state dependent XCorr scores C1.5, 2.5, and 3.0
for 1?,2 ?, and 3? peptides, respectively, and DCn scores[0.1 were the criteria for positive identiﬁcations
N N-terminal projection domain, P Pro-rich region, M microtubule-binding domain, R1, R2 repeat regions 1 and 2, respectively
Fig. 2 Relative abundance of PHF-tau methylation and ubiquityla-
tion. Relative abundance was calculated based on the spectral counts
of the modiﬁed peptide/(modiﬁed peptide ? unmodiﬁed peptide).
Only sites having total spectral counts[3 are shown. Inset quantiﬁes
K254 methylation (41%) and ubiquitylation (1%). K254 was the most
abundant methylated site identiﬁed on PHF-tau (spectral count = 17)
and the only site on PHF-tau identiﬁed in methylated and ubiquity-
lated forms
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iquitylation at K254, and that monomethylation of this site
is far more abundant than ubiquitylation in PHF-tau
(Fig. 2, inset).
Lys methylation and potential cross talk
with phosphorylation
Although several of the monomethylation sites on PHF-tau
lie within ﬁve amino acid residues of phosphorylation sites
identiﬁed in the literature [25], only one peptide
(aa258–267) was detected in our data sets that contained
both a methylated lysine and a phosphorylated hydroxy
amino acid. The phosphorylation site in this peptide, S262,
functions as a regulatory gatekeeper for microtubule
association, with site occupancy correlating with decreased
binding afﬁnity [38, 58]. Its proximity to K267 allowed us
to detect relative site occupancy within a short peptide
sequence. Unmodiﬁed aa258–267 was identiﬁed as a Lys-
C derived peptide from its MS/MS spectrum (Fig. 4a).
Relative to the 1? charge state y-ions of this peptide, the y-
ions of methylated aa258–267 peptide were shifted by
?14 Da, reﬂecting the mass of the methyl group added to
the e-amino group of K267 (Fig. 4b). In contrast, the
assigned y7- and y8-ions of aa258–267 phosphorylated at
S262 were shifted by -18 Da, consistent with the domi-
nant ion having undergone neutral loss of H3PO4 by b-
elimination ([3]; Fig. 4c). Peptide aa258–267 also was
detected in a doubly modiﬁed (phosphorylated and meth-
ylated) form. Consistent with the behavior of
phosphopeptides, the MS/MS spectrum of this peptide was
dominated by a precursor ion that had undergone b-elim-
ination (Fig. 4d).
To quantify the modiﬁcation signature of these peptides,
their relative abundance was measured by spectral counting
(Table 3). Results revealed that the singly modiﬁed
methyl-K267 peptide was the most abundant form (spectral
count = 6; 35% of total aa258–267 peptide spectral count),
and relative abundance followed the pattern: methyl-
K267 * methyl-K267/phospho-S262[phospho-
S262 * un-modiﬁed K267/S262. Thus monomethylation
at K267 was a more abundant PHF-tau modiﬁcation than
was phosphorylation at S262, with the latter being found
more frequently in the presence of K267 methylation than
found alone.
Methyl-lysine immunoreactivity associates
with the neuroﬁbrillary lesions of AD
In AD, PHF-tau accumulates within neuroﬁbrillary lesions
associated with neuronal cell bodies (NFTs), neuronal
processes (neuropil threads), and the dystrophic neurites of
Fig. 3 MS/MS characterization of K254 modiﬁcation site. Spectra
for peptide aa241–254 derived from Lys-C cleavage of PHF-tau
identiﬁed in (a) unmodiﬁed and (b) methylated (asterisks site of
methylation) forms. c Spectrum for tryptic peptide aa243–257
identiﬁed in ubiquitylated form (carets site of ubiquitylation). Trypsin
did not cleave ubiquitylated aa243–257 at K254 owing to its
conjugation to the C-terminal di-Gly fragment of ubiquitin
110 Acta Neuropathol (2012) 123:105–117
123Fig. 4 MS/MS identiﬁcation of S262 phosphorylated and K267
methylated PHF-tau peptides. Spectra for PHF-tau derived peptide
aa258–267 identiﬁed in a unmodiﬁed, b monomethylated (asterisks
site of methylation), c Ser phosphorylated (at sign site of phosphor-
ylation), and d doubly modiﬁed (asterisks site of methylation; at sign
site of phosphorylation) forms
Table 2 Relative abundances of methylated and ubiquitylated PHF-tau peptides as assessed by spectral counts
aa Residues Peptide Modiﬁcation site Spectral count % Modiﬁed
Modiﬁed Un-modiﬁed Total
25–44 DQGGYTMHQDQEGDTDAGLK meK44 11 18 29 38%
151–163 IATPRGAAPPGQK meK163 2 6 8 25%
164–174 GQANATRIPAK meK174 2 n.d. 2 n.d.
175–180 TPPAPK meK180 2 1 3 67%
241–254 SRLQTAPVPMPDLK meK254 17 24 41 41%
243–257 LQTAPVPMPDLKNVK ub-K254 2 188 190 1%
258–267 SKIGSTENLK meK267 6 3 9 67%
281–290 KLDLSNVQSK meK290 2 14 16 12%
299–317 HVPGGGSVQIVYKPVDLSK ub-K311 5 10 15 33%
350–369 VQSKIGSLDNITHVPGGGNK ub-K353 2 49 51 4%
Spectral counts are deﬁned as the number of times a peptide was identiﬁed by MS/MS. Amino acids in bold indicate identiﬁed methylated Lys
residues. % Modiﬁed is calculated based on the following spectral counts: modiﬁed peptide/(modiﬁed peptide ? un-modiﬁed peptide)
n.d. not detected, me methylation, ub ubiquitylation
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123neuritic plaques [8]. To determine whether tau methylation
correlated spatially with neuroﬁbrillary pathology, sections
of AD brain hippocampus were probed with a polyclonal
antibody that binds meK-containing proteins along with
well-characterized monoclonal anti-tau antibodies AT8 and
Tau5 [5, 43] in double label format. These tau antibodies
were chosen for analysis because their epitopes are present
during all phases of NFT development, including the early
pre- and intracellular-NFT stages [60]. The speciﬁcity of
the anti-meK reagent was ﬁrst tested on recombinant 2N4R
tau preparations that were subjected to reductive methyl-
ation in vitro (see materials and methods). When subjected
to SDS-PAGE, both non-methylated and methylated 2N4R
tau migrated as single species, with the latter undergoing a
band shift to 73 kDa (Fig. 5a). Rabbit polyclonal anti-meK
antibody strongly labeled this species but not nonmethy-
lated 2N4R tau (Fig. 5b). Binding speciﬁcity was further
characterized by preadsorption assay, where antibodies
were preincubated with 2000-fold molar excess of either
non-methylated or methylated 2N4R tau before being used
for immunohistochemical labeling of the hippocampal
brain sections. When AT8 was preadsorbed under these
conditions, neither non-methylated nor methylated tau
preparations diminished its reactivity toward neuroﬁbril-
lary lesions (detected by confocal immunoﬂuorescence
microcopy; Fig. 5c, f). These data were consistent with the
established anti-phosphoepitope binding speciﬁcity of AT8
[22]. Anti-meK antibody also labeled neuroﬁbrillary
lesions in these sections, and like AT8, its labeling inten-
sity was not affected by preadsorption with non-methylated
2N4R tau (Fig. 5d). However, labeling intensity was
greatly diminished by pre-adsorption with methylated
2N4R tau (Fig. 5g). Together these data are consistent with
the anti-meK antibody being selective for lysine methyl-
ated proteins.
Double-label confocal immunoﬂuorescence studies were
then extended to hippocampal brain sections prepared from
four cognitively normal and six late-stage AD cases (case
demographics are summarized in Table 4). In normal tis-
sue, AT8, Tau5, and anti-meK antibody staining was
diffuse and rarely colocalized (shown for AT8 and anti-
meK antibody in Fig. 6a–c). In contrast, both AT8
(Fig. 6d–i) and Tau 5 (Fig. 6j–o) strongly labeled neuro-
ﬁbrillary lesions in AD hippocampal sections, including
NFTs, neuropil threads, and neuritic plaques. At high
magniﬁcation, NFTs immunolabeled with Tau5 displayed a
ﬁbrillar pattern throughout the lesions (Fig. 6m), whereas
those labeled with AT8 also displayed a pattern of intense
immunoreactivity enriched on the outer rims of the lesions
(Fig. 6g). Rim staining, which has been seen previously
with AT8 [28], was particularly conspicuous at low ﬂuo-
rescence gain. In contrast, anti-meK immunoreactivity
appeared diffusely distributed throughout the sections
(Fig. 6e, h, k, n), with the most intense labeling correlating
with both AT8- and Tau5-stained lesions (Fig. 6d–o). In
particular, the pattern of labeling with NFTs resembled that
of Tau5, with ﬁbrillar staining throughout the lesion
(Fig. 6m–o). Although background ﬂuorescence was gen-
erally too high to detect neuropil threads with the anti-meK
antibody, colocalization with particularly large or intense
dystrophic neurites was occasionally seen (Fig. 6j–l). NFT
labeling was robust, however, and so colocalization of
meK immunoreactivity with this lesion was quantiﬁed in
hippocampus CA1 region. Results showed that the majority
of NFTs labeled with anti-meK antibody in all six cases
(Table 4). Overall, anti-meK colocalization with AT8-
labeled NFTs averaged 78 ± 11% (SD, n = 6 cases)
whereas colocalization with Tau5-labeled NFTs averaged
79 ± 16% (SD, n = 6 cases). Together these data show
that the methylation of PHF-tau identiﬁed through mass
spectrometry is widespread in this affected brain region,
with most NFTs harboring anti-meK immunoreactivity in
late-stage AD.
Discussion
Although certain familial tauopathies result from missense
mutations in the tau gene (MAPT), AD pathogenesis is
not associated with changes in tau amino acid sequence.
Rather, tau lesion formation in sporadic AD is accom-
panied by PTMs that contribute to pathogenesis by
modulating tau function, stability, and aggregation pro-
pensity. Because neuroﬁbrillary lesion density correlates
with neurodegeneration [24, 31] and cognitive decline
[19, 20, 55], a high priority in the AD ﬁeld is to identify
the PTM signature that drives neuroﬁbrillary lesion for-
mation in sporadic disease. Here we found that PHF-tau
isolated from neocortical areas is methylated at at least
seven distinct sites, and that the modiﬁcation is wide-
spread among NFTs in the CA1 region of hippocampus in
late stage AD. These ﬁndings suggest that tau methylation
is a component of the PTM signature associated with
PHF-tau.
Table 3 Relative abundance of S262 phosphorylated and K267
methylated PHF-tau peptides (aa258–267)
Peptide (aa258–267) Spectral count % Relative
abundance
Unmodiﬁed 3 18
Phospho-S262 3 18
Phospho-S262, meK267 5 29
meK267 6 35
Relative abundances were calculated by dividing the peptide spectral
count for each peptide of interest by the total count for all peptides
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123Fig. 5 Anti-meK antibody speciﬁcity. Aliquots of unmodiﬁed (-)
and in vitro methylated (?) 2N4R tau were separated by SDS-PAGE
(8% polyacrylamide) and either a stained with Coomassie Blue
(500 ng tau proteins), or b subjected to immunoblot analysis with
anti-meK antibody (100 ng tau protein). Molecular mass calibration
markers (M) are shown in units of kDa. High-stoichiometry reductive
methylation reduced recombinant 2N4R migration on SDS-PAGE. To
further test speciﬁcity, antibodies AT8 (c, f; green channel) and anti-
meK (d, g; red channel) were pre-adsorbed with either unmodiﬁed
(c–e) or in vitro methylated (f–h) 2N4R tau, and then subjected to
double-label confocal immunoﬂuorescence microscopy on sections of
AD hippocampus. Lesions labeled with both AT8 and anti-meK are
marked by asterisks. AT8 labeling was unaffected by preadsorption
with either unmodiﬁed or methylated tau, whereas anti-meK immu-
noreactivity was diminished by pre-adsorption with methylated (f–h;
carets), but not unmodiﬁed tau (c–e)
Table 4 Case demographics and marker colocalization in hippocampus CA1 region
Case (#) Age (years) Gender PMI (h) Diagnosis meK/AT8
colocalization
± SE (%)
n meK/Tau5
colocalization
± SE (%)
n
1 61 M 5.3 AD, Braak stage V–VI 86 ± 84 3 9 2 ± 63 6
2 81 F – AD; Braak stage V–VI, vascular involvement 89 ± 73 9 8 9 ± 83 6
3 81 M 4.1 AD; Braak stage VI, vascular involvement 78 ± 6 154 82 ± 5 168
4 82 F 4.0 AD, Braak stage V–VI 78 ± 7 115 90 ± 67 0
5 86 M 3.2 AD, Braak stage V–VI 59 ± 12 70 52 ± 10 97
6 87 M 2.5 AD, Braak stage V–VI 75 ± 14 28 71 ± 13 35
7 52 M 6.5 Control, myocardial infarct – – – –
8 57 M 7.5 Control, cardiac failure – – – –
9 64 M 7.0 Control – – – –
10 75 M 8.2 Control, liver failure – – – –
PMI post mortem interval, n number of lesions quantiﬁed
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123The direct effects of Lys methylation on tau function are
not known, but in other proteins this modiﬁcation is
reported to modulate protein–protein interaction by
increasing the interaction radius of Lys side chains [34] and
by increasing the entropic driving force for its burial away
from solvent [62]. For these reasons, reductive methylation
is used to improve the performance of protein crystalliza-
tion in preparation for diffraction experiments [34]. The
localization of methylated residues within the microtubule
binding repeat region in proximity to the PHF6 and PHF6*
nucleation centers makes Lys methylation a candidate
modiﬁcation for directly affecting normal tau interactions
with binding partners such as microtubules as well as
abnormal interactions such as aggregation and PHF
formation.
In addition to direct effects, Lys methylation also may
modulate protein function through cross-talk with other
PTMs. In its simplest form, crosstalk involves direct
Fig. 6 Anti-meK
immunoreactivity colocalizes
with neuroﬁbrillary lesions in
AD hippocampus. Double-label
confocal images of hippocampal
sections (CA1 region) stained
with anti-tau mouse monoclonal
antibodies AT8 (a–i; green
channel) or Tau5 (j–o; green
channel) along with the rabbit
anti-meK antibody (red
channel). In AD cases, low
magniﬁcation images (409
objective,19 zoom) show
colocalization of anti-meK
immunoreactivity with NFTs
(d–f; asterisks) and a neuritic
plaque (j–l; arrows). High
magniﬁcation images (1009
objective, 39 zoom) show
typical morphology of NFTs (g–
i and m–o). Image overlays
highlight pixel overlap between
anti-meK and AT8 (d–i) and
Tau5 (j–o) immunoreactivity.
Anti-meK immunoreactivity
colocalized extensively with
NFTs in all ﬁelds examined. In
contrast, AT8 and anti-meK
immunoreactivity did not
colocalize in hippocampal
sections prepared from
cognitively normal cases (a–c)
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123competition for occupancy of any single amino acid resi-
due side chain. Here we found that K254 from PHF-tau
isolated from AD brains was either ubiquitylated or
methylated, with the latter strongly predominating. These
data indicate that K254 methylation must occur at the
expense of ubiquitylation, and thus is a candidate modiﬁ-
cation for regulating protein degradation via the ubiquitin–
proteasome system [46].
A second, more complex paradigm of crosstalk involves
interactions between separate amino acid residues, where
modiﬁcation of one residue alters the ability of a second
residue to bind its modifying enzyme. For example, tau
phosphorylated by the microtubule afﬁnity-regulating
kinase 2 (PAR1/MARK2) is not recognized by the CHIP/
Hsp90 E3 ligase complex and thus fails to be ubiquitylated
or degraded [15]. Conversely, tau requires phosphorylation
by GSK3b for efﬁcient recognition and ubiquitylation by
the CHIP/Hsp90 complex [61]. Here we found that K267 is
methylated in PHF-tau, and that phosphorylation of S262
appears more frequently on peptides containing methylated
rather than non-methylated K267. This observation raises
the possibility of crosstalk between S262 phosphorylation,
which strongly reduces the binding of tau to microtubules
[4, 58], and K267 methylation. The impaired microtubule-
binding phenotype associated with S262 phosphorylation
may be important for AD pathogenesis since this site is
occupied early in NFT formation [2]. Other sites of phos-
phorylation identiﬁed previously in PHF-tau [25] (but not
found in our datasets) also lie within close proximity to
methylation sites. These include T175, T181, S184, S185,
S258, and S289. Moreover, one projection domain meth-
ylation site, K44, is adjacent to a predicted calpain-
catalyzed cleavage site in tau [52]. These data suggest that
tau methylation is positioned to potentially engage in cross
talk with multiple post translational modiﬁcations. It will
be important to establish the temporal relationship among
these modiﬁcations and the aggregation of tau during
neuroﬁbrillary lesion formation in AD. Mass spectrometry
can complement high throughput immunohistochemical
detection methods, which are sensitive to modiﬁcation
context [16], in this effort.
Comparison with previous studies
Previous characterization of PHFs prepared by differential
centrifugation using amino acid analysis reported a low
unmodiﬁed Lys content relative to predicted tau composi-
tion, consistent with extensive Lys modiﬁcation, but failed
to detect meK [42]. The source of this discrepancy is not
clear, but may relate to the sensitivity of amino acid
analysis relative to MS and to the purity of the PHF
preparations used for study.
Two recent studies reported that tau can be acetylated on
Lys in vitro, resulting in increased aggregation propensity
and inhibition of tau degradation [11, 46]. In vivo acety-
lation of K163, K174, K180 and K280 and accumulation
within PHF-tau was claimed on the basis of antibody-based
methods in tissue sections prepared from AD and fronto-
temporal lobar degeneration cases [11, 46]. On the basis of
MS analysis, we did not detect tau acetylation even though
residues K163, K174, K180 and K280 were resolved
within our coverage area. These discrepancies could arise
from any of several possibilities. One is that methylation
occurs to a greater extent than acetylation. Consistent with
this model, we found that K163, K174, and K180 were
modiﬁed in PHF, but by monomethylation rather than
acetylation. Combined with our detection of Lys ubiqui-
tylation, these data suggest that the relative abundances of
Lys methylation and ubiquitylation are likely higher than
Lys acetylation in the PHF-tau preparation used herein.
Another possibility is that PHF-tau contains substantial
acetylation, but at sites distinct from those identiﬁed in
vitro or that reside within our current coverage area.
Additional analysis of PHF will be required to test this
hypothesis. A third possibility is that immunopuriﬁed PHF
represents a subfraction of tau aggregates with greater
SDS-solubililty. For example, we ﬁnd ([13]; Fig. 1) that
immunopuriﬁed PHFs lack detectable phosphorylation at
T175 and T181 that were reported qualitatively by others in
some tissue/PHF preparations [2, 21, 26]. In addition, Y394
phosphorylation has been reported in PHF-tau [14, 63], but
this modiﬁcation is present at rather low relative abundance
in the PHF-tau preparation used herein. It should be pos-
sible to resolve these possibilities in the future using mass
spectrometry under conditions that provide quantitative
information on modiﬁcation occupancy.
In conclusion, we report biophysical evidence that seven
Lys residues (K44, K163, K174, K180, K254, K267, and
K290) in PHF-tau immunopuriﬁed from AD brain are
monomethylated. The sites present opportunities for cross
talk with other PTMs, including direct competition with
ubiquitylation and acetylation, and indirect interaction with
phosphorylation and proteolysis. It will be important to
determine the functional and temporal relationships among
these established modiﬁcations in modulating the accu-
mulation of PHF-tau in AD and other age-related
neurodegenerative diseases.
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